Forian Inc. Announces Fourth Quarter and Full Year 2023 Financial Results
Full Year 2023 Revenue Grew 25% Full Year 2023 Adjusted EBITDA of $2.3MM NEWTOWN, PA, March 28, 2024 (GLOBE NEWSWIRE) […]
Full Year 2023 Revenue Grew 25% Full Year 2023 Adjusted EBITDA of $2.3MM NEWTOWN, PA, March 28, 2024 (GLOBE NEWSWIRE) […]
Full-year sales increased 11% to $1.57 billion Fiscal 2023 GAAP EPS of $3.82 impacted by noncash impairment charges of $5.32 […]
REDWOOD CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted […]
Record consolidated net revenue of $84.5 million for full-year 2023 Fortress may receive up to four regulatory decisions on NDAs […]
SCOTTSDALE, Ariz., March 28, 2024 (GLOBE NEWSWIRE) — TPI Composites, Inc. (Nasdaq: TPIC), today published its 2023 sustainability report highlighting its […]
— Company to host call at 4:30pm today — NEWTOWN, Pa., March 28, 2024 (GLOBE NEWSWIRE) — Helius Medical Technologies, […]
GAITHERSBURG, Md., March 28, 2024 (GLOBE NEWSWIRE) — Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering […]
Four candidates planned to be in clinical development in 2024 with interim data from two studies anticipated by year end […]
Announced Phase 2a study of SLS009 in r/r AML Showing 50% Response Rate in the Selected Optimal Dose of 30 […]
ASML cautions investors regarding Tutanota LLC’s “mini-tender” offer VELDHOVEN, the Netherlands, March 28, 2024 – ASML Holding NV (ASML) today […]